Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.45 |
| ▸ | BRD4 | O60885 | 5/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15512353 | 0.89 | GPR119 (0.59) | SLC6A9KCNH2GPR119SCN9A | |
| SCHEMBL15511253 | 0.89 | GPR119 (0.59) | SLC6A9KCNH2GPR119SCN9A | |
| SCHEMBL15495865 | 0.89 | GPR119 (0.59) | SLC6A9KCNH2GPR119SCN9A | |
| SCHEMBL15511762 | 0.85 | SLC6A9 (0.59) | SLC6A9KCNH2GPR119BRD4 | |
| SCHEMBL15511763 | 0.85 | SLC6A9 (0.59) | SLC6A9KCNH2GPR119BRD4 | |
| SCHEMBL15511723 | 0.81 | SLC6A9 (0.53) | SLC6A9KCNH2GPR119BRD4CYP2C9 | |
| SCHEMBL13733784 | 0.81 | SLC6A9 (0.53) | SLC6A9KCNH2GPR119BRD4CYP2C9 | |
| SCHEMBL15511957 | 0.81 | SLC6A9 (0.55) | SLC6A9KCNH2GPR119BRD4 | |
| SCHEMBL15511110 | 0.81 | SLC6A9 (0.53) | SLC6A9KCNH2GPR119BRD4CYP2C9 | |
| SCHEMBL15518261 | 0.81 | SLC6A9 (0.53) | SLC6A9KCNH2GPR119BRD4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | SLC6A9 91/4885KCNH2 1221/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.